Last updated on May 2019

INOVATYON STUDY -International Randomized Study in Patients With Ovarian Cancer

Brief description of study

The objective of this multicentric, randomised, Phase III study is to demonstrate superiority, in terms of prolonged survival, of trabectedin and Pegylated Liposomal Doxorubicin (PLD) versus carboplatin and PLD.

Patients will be randomised to:

Arm A: PLD 30 mg/m2 and carboplatin AUC 5 Arm B: PLD 30 mg/m2 and trabectedin 1.1 mg/m2 Patients'/subjects' characteristics: patients over 18 years of age with advanced, progressive ovarian cancer 6-12 months after completion of first line treatment with platinum-based chemotherapy.

Clinical Study Identifier: NCT01379989

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.